Limits...
Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer.

Fujimoto N, Kubo T, Shinsaka H, Matsumoto M, Shimajiri S, Matsumoto T - BMC Urol (2011)

Bottom Line: Factors associated with pT0, which is regarded as serious cancer cell damage or elimination, were investigated.Of the 68 males, 24 (35.3%) were classified as pT0.No other clinical characteristics predicted conversion to pT0.

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu 807-8555, Japan. n-fuji@med.uoeh-u.ac.jp

ABSTRACT

Background: Primary androgen deprivation therapy (ADT) is a treatment option not only for advanced but also for localized prostate cancer. However, the appropriate duration for primary ADT for localized prostate cancer has not been defined and few studies have addressed this issue. In this study, we aimed to determine the appropriate duration of ADT for localized prostate cancer.

Methods: Sixty-eight consecutive patients with localized prostate cancer who underwent a prostatectomy following neoadjuvant ADT were retrospectively reviewed. Factors associated with pT0, which is regarded as serious cancer cell damage or elimination, were investigated.

Results: Of the 68 males, 24 (35.3%) were classified as pT0. The median duration of neoadjuvant ADT in the pT0 and non-pT0 groups was 9 months and 7.5 months, respectively (p = 0.022). The duration of neoadjuvant ADT from when PSA reached < 0.2 ng/ml to surgery was longer in the pT0 group than that in the non-pT0 group (median 5 months against 3 months, p = 0.011). pT0 was achieved in 5 of 6 patients (83.3%) who received ADT for ≥10 months after PSA reached < 0.2 ng/ml. No other clinical characteristics predicted conversion to pT0.

Conclusions: Continuous ADT for ≥10 months after PSA reached < 0.2 ng/ml induced serious prostate cancer cell damage in most patients (> 80%) and may be sufficient to treat localized prostate cancer.

Show MeSH

Related in: MedlinePlus

Duration of ADT: total (A), before (B), and after (C) PSA reached < 0.2 ng/ml or its nadir.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3116482&req=5

Figure 1: Duration of ADT: total (A), before (B), and after (C) PSA reached < 0.2 ng/ml or its nadir.

Mentions: The PSA values before and after ADT, clinical stages, Gleason score and risk classification did not predict conversion into pT0. The median duration of neoadjuvant ADT in the pT0 and non-pT0 groups was 9 months and 7.5 months, respectively (p = 0.022). When the duration of neoadjuvant ADT was divided into before and after PSA reached < 0.2 ng/ml or its nadir, the median duration before PSA reached < 0.2 ng/ml or its nadir was 3 months in both the pT0 and non-pT0 groups. In contrast, the median duration after PSA reached < 0.2 ng/ml or its nadir was 5 months and 3 months in the pT0 and non-pT0 groups, respectively. A longer duration after PSA reached < 0.2 ng/ml or its lowest value was significantly associated with pT0 classification (p = 0.011, Figure 1). pT0 frequency increased with a longer duration of ADT after the PSA reached < 0.2 ng/ml or lits nadir. Five of six (83.3%) patients who received ADT for ≥10 months after PSA reached < 0.2 ng/ml achieved pT0 (Figure 2) and this ratio was significantly higher than that in patients treated with ADT for shorter durations (p = 0.0099).


Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer.

Fujimoto N, Kubo T, Shinsaka H, Matsumoto M, Shimajiri S, Matsumoto T - BMC Urol (2011)

Duration of ADT: total (A), before (B), and after (C) PSA reached < 0.2 ng/ml or its nadir.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3116482&req=5

Figure 1: Duration of ADT: total (A), before (B), and after (C) PSA reached < 0.2 ng/ml or its nadir.
Mentions: The PSA values before and after ADT, clinical stages, Gleason score and risk classification did not predict conversion into pT0. The median duration of neoadjuvant ADT in the pT0 and non-pT0 groups was 9 months and 7.5 months, respectively (p = 0.022). When the duration of neoadjuvant ADT was divided into before and after PSA reached < 0.2 ng/ml or its nadir, the median duration before PSA reached < 0.2 ng/ml or its nadir was 3 months in both the pT0 and non-pT0 groups. In contrast, the median duration after PSA reached < 0.2 ng/ml or its nadir was 5 months and 3 months in the pT0 and non-pT0 groups, respectively. A longer duration after PSA reached < 0.2 ng/ml or its lowest value was significantly associated with pT0 classification (p = 0.011, Figure 1). pT0 frequency increased with a longer duration of ADT after the PSA reached < 0.2 ng/ml or lits nadir. Five of six (83.3%) patients who received ADT for ≥10 months after PSA reached < 0.2 ng/ml achieved pT0 (Figure 2) and this ratio was significantly higher than that in patients treated with ADT for shorter durations (p = 0.0099).

Bottom Line: Factors associated with pT0, which is regarded as serious cancer cell damage or elimination, were investigated.Of the 68 males, 24 (35.3%) were classified as pT0.No other clinical characteristics predicted conversion to pT0.

View Article: PubMed Central - HTML - PubMed

Affiliation: Department of Urology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu 807-8555, Japan. n-fuji@med.uoeh-u.ac.jp

ABSTRACT

Background: Primary androgen deprivation therapy (ADT) is a treatment option not only for advanced but also for localized prostate cancer. However, the appropriate duration for primary ADT for localized prostate cancer has not been defined and few studies have addressed this issue. In this study, we aimed to determine the appropriate duration of ADT for localized prostate cancer.

Methods: Sixty-eight consecutive patients with localized prostate cancer who underwent a prostatectomy following neoadjuvant ADT were retrospectively reviewed. Factors associated with pT0, which is regarded as serious cancer cell damage or elimination, were investigated.

Results: Of the 68 males, 24 (35.3%) were classified as pT0. The median duration of neoadjuvant ADT in the pT0 and non-pT0 groups was 9 months and 7.5 months, respectively (p = 0.022). The duration of neoadjuvant ADT from when PSA reached < 0.2 ng/ml to surgery was longer in the pT0 group than that in the non-pT0 group (median 5 months against 3 months, p = 0.011). pT0 was achieved in 5 of 6 patients (83.3%) who received ADT for ≥10 months after PSA reached < 0.2 ng/ml. No other clinical characteristics predicted conversion to pT0.

Conclusions: Continuous ADT for ≥10 months after PSA reached < 0.2 ng/ml induced serious prostate cancer cell damage in most patients (> 80%) and may be sufficient to treat localized prostate cancer.

Show MeSH
Related in: MedlinePlus